Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christine Carreira is active.

Publication


Featured researches published by Christine Carreira.


Journal of the National Cancer Institute | 2013

Human Papillomavirus Infections and Upper Aero-Digestive Tract Cancers: The ARCAGE Study

Devasena Anantharaman; Tarik Gheit; Tim Waterboer; Behnoush Abedi-Ardekani; Christine Carreira; Sandrine McKay-Chopin; Valerie Gaborieau; Manuela Marron; Pagona Lagiou; Wolfgang Ahrens; Ivana Holcatova; Franco Merletti; Kristina Kjaerheim; Renato Talamini; Lorenzo Simonato; Xavier Castellsagué; Tatiana V. MacFarlane; Anne Marie Biggs; Nalin Thakker; Ariana Znaor; Peter Thomson; Cristina Canova; David I. Conway; Claire M. Healy; Massimo Tommasino; Michael Pawlita; Paul Brennan

BACKGROUND Human papillomavirus (HPV) is causally implicated in a subset of cancers of the upper aero-digestive tract (UADT). METHODS Associations between type-specific HPV antibodies were examined among 1496 UADT cancer case subjects and 1425 control subjects by estimating odds ratios (ORs) in logistic regression analyses adjusted for potential confounders. The agreement between serology and tumor markers of HPV infection, including presence of HPV DNA and p16 expression, were examined in a subset of tumors. RESULTS HPV16 L1 seropositivity was associated with increased risk of oral cavity and oropharyngeal cancer (OR = 1.94, 95% confidence interval [CI] = 1.03 to 3.65; OR = 8.60, 95% CI = 5.21 to 14.20, respectively). HPV16 E6 antibodies were present in 30.2% of oropharyngeal case subjects and only 0.8% of control subjects (OR = 132.0, 95% CI = 65.29 to 266.86). Combined seropositivity to HPV16 E6 and E7 was rare (n = 1 of 1425 control subjects). An agreement of 67% was observed between HPV16 E6 serology and the corresponding presence of an HPV-related cancer: four of six HPV DNA-positive/p16-overexpressing tumors were HPV16 E6 antibody positive. An HPV16 independent association was observed for HPV18 and oropharyngeal cancer (OR = 8.14, 95% CI = 2.21 to 29.99 for HPV18 E6 seropositivity) and HPV6 and laryngeal cancer (OR = 3.25, 95% CI = 1.46 to 7.24 for HPV6 E7 seropositivity). CONCLUSIONS These results confirm an important role for HPV16 infection in oropharyngeal cancer. HPV16 E6 antibodies are strongly associated with HPV16-related oropharyngeal cancers. Continuing efforts are needed to consider both HPV serology and p16 staining as biomarkers relevant to the etiology and natural history of HPV16-related oropharyngeal tumors. These results also support a marginal role for HPV18 in oropharyngeal cancer and HPV6 in laryngeal cancer.


Journal of Experimental Medicine | 2013

The Human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter

Uzma Hasan; Claudia Zannetti; Peggy Parroche; Nadège Goutagny; Marine Malfroy; Guillaume Roblot; Christine Carreira; Ishraq Hussain; Martin Müller; Joyce Taylor-Papadimitriou; Didier Picard; Bakary S. Sylla; Giorgio Trinchieri; Ruslan Medzhitov; Massimo Tommasino

HPV16-positive cervical cancer lesions contain NFκB–ERα nuclear complexes to repress the TLR9 promoter.


PLOS ONE | 2013

Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States.

Magdalena B. Wozniak; Florence Le Calvez-Kelm; Behnoush Abedi-Ardekani; Graham Byrnes; Geoffroy Durand; Christine Carreira; Jocelyne Michelon; Vladimir Janout; Ivana Holcatova; Lenka Foretova; Antonin Brisuda; Fabienne Lesueur; James D. McKay; Paul Brennan; Ghislaine Scelo

Gene expression microarray and next generation sequencing efforts on conventional, clear cell renal cell carcinoma (ccRCC) have been mostly performed in North American and Western European populations, while the highest incidence rates are found in Central/Eastern Europe. We conducted whole-genome expression profiling on 101 pairs of ccRCC tumours and adjacent non-tumour renal tissue from Czech patients recruited within the “K2 Study”, using the Illumina HumanHT-12 v4 Expression BeadChips to explore the molecular variations underlying the biological and clinical heterogeneity of this cancer. Differential expression analysis identified 1650 significant probes (fold change ≥2 and false discovery rate <0.05) mapping to 630 up- and 720 down-regulated unique genes. We performed similar statistical analysis on the RNA sequencing data of 65 ccRCC cases from the Cancer Genome Atlas (TCGA) project and identified 60% (402) of the downregulated and 74% (469) of the upregulated genes found in the K2 series. The biological characterization of the significantly deregulated genes demonstrated involvement of downregulated genes in metabolic and catabolic processes, excretion, oxidation reduction, ion transport and response to chemical stimulus, while simultaneously upregulated genes were associated with immune and inflammatory responses, response to hypoxia, stress, wounding, vasculature development and cell activation. Furthermore, genome-wide DNA methylation analysis of 317 TCGA ccRCC/adjacent non-tumour renal tissue pairs indicated that deregulation of approximately 7% of genes could be explained by epigenetic changes. Finally, survival analysis conducted on 89 K2 and 464 TCGA cases identified 8 genes associated with differential prognostic outcomes. In conclusion, a large proportion of ccRCC molecular characteristics were common to the two populations and several may have clinical implications when validated further through large clinical cohorts.


Molecular and Cellular Biology | 2011

IκB Kinase β Promotes Cell Survival by Antagonizing p53 Functions through ΔNp73α Phosphorylation and Stabilization

Rosita Accardi; Mariafrancesca Scalise; Tarik Gheit; Ishraq Hussain; Jiping Yue; Christine Carreira; Agnese Collino; Cesare Indiveri; Lutz Gissmann; Bakary S. Sylla; Massimo Tommasino

ABSTRACT ΔNp73α, a dominant-negative inhibitor of p53 and p73, exhibits antiapoptotic and transforming activity in in vitro models and is often found to be upregulated in human cancers. The mechanisms involved in the regulation of ΔNp73α protein levels in normal and cancer cells are poorly characterized. Here, we show that that IκB kinase beta (IKKβ) increases ΔNp73α protein stability independently of its ability to activate NF-κB. IKKβ associates with and phosphorylates ΔNp73α at serine 422 (S422), leading to its accumulation in the nucleus, where it binds and represses several p53-regulated genes. S422A mutation in ΔNp73α abolished IKKβ-mediated stabilization and inhibition of p53-regulated gene expression. Inhibition of IKKβ activity by chemical inhibitors, overexpression of dominant-negative mutants, or gene silencing by siRNA also resulted in ΔNp73α destabilization, which under these conditions was rapidly translocated into the cytoplasm and degraded by a calpain-mediated mechanism. We also present evidence for the IKKβ and ΔNp73α cross talk in cancer-derived cell lines and primary cancers. Our data unveil a new mechanism involved in the regulation of the p73 and p53 network.


Cancer Research | 2014

No causal association identified for human papillomavirus infections in lung cancer

Devasena Anantharaman; Tarik Gheit; Tim Waterboer; Gordana Halec; Christine Carreira; Behnoush Abedi-Ardekani; Sandrine McKay-Chopin; David Zaridze; Anush Mukeria; Neonila Szeszenia-Dabrowska; Jolanta Lissowska; Dana Mates; Vladimir Janout; Lenka Foretova; Vladimir Bencko; Peter Rudnai; Eleonora Fabianova; Anne Tjønneland; Ruth C. Travis; Heiner Boeing; J. Ramón Quirós; Mikael Johansson; Vittorio Krogh; H. Bas Bueno-de-Mesquita; Anastasia Kotanidou; Françoise Clavel-Chapelon; Elisabete Weiderpass; Mattias Johansson; Michael Pawlita; Ghislaine Scelo

Human papillomavirus (HPV) infections have been implicated in lung carcinogenesis, but causal associations remain uncertain. We evaluated a potential causal role for HPV infections in lung cancer through an analysis involving serology, tumor DNA, RNA, and p16 protein expression. Association between type-specific HPV antibodies and risk of lung cancer was examined among 3,083 cases and 4,328 controls in two case-control studies (retrospective) and one nested case-control study (prospective design). Three hundred and thirty-four available tumors were subjected to pathologic evaluation and subsequent HPV genotyping following stringent conditions to detect all high-risk and two low-risk HPV types. All HPV DNA-positive tumors were further tested for the expression of p16 protein and type-specific HPV mRNA. On the basis of the consistency of the results, although HPV11 and HPV31 E6 antibodies were associated with lung cancer risk in the retrospective study, no association was observed in the prospective design. Presence of type-specific antibodies correlated poorly with the presence of the corresponding HPV DNA in the tumor. Although nearly 10% of the lung tumors were positive for any HPV DNA (7% for HPV16 DNA), none expressed the viral oncogenes. No association was observed between HPV antibodies or DNA and lung cancer survival. In conclusion, we found no supportive evidence for the hypothesized causal association between HPV infections and lung cancer.


BMC Cancer | 2010

Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice

Christelle Seigne; Sandra Fontanière; Christine Carreira; Jieli Lu; Wei-Ming Tong; Bernard Fontanière; Zhao-Qi Wang; Chang Xian Zhang; Lucien Frappart

BackgroundMutations of the MEN1 gene predispose to multiple endocrine neoplasia type 1 (MEN1) syndrome. Our group and others have shown that Men1 disruption in mice recapitulates MEN1 pathology. Intriguingly, rare lesions in hormone-dependent tissues, such as prostate and mammary glands, were also observed in the Men1 mutant mice.MethodsTo study the occurrence of prostate lesions, we followed a male mouse cohort of 47 Men1+/- mice and 23 age-matched control littermates, starting at 18 months of age, and analysed the prostate glands from the cohort.ResultsSix Men1+/- mice (12.8%) developed prostate cancer, including two adenocarcinomas and four in situ carcinomas, while none of the control mice developed cancerous lesions. The expression of menin encoded by the Men1 gene was found to be drastically reduced in all carcinomas, and partial LOH of the wild-type Men1 allele was detected in three of the five analysed lesions. Using immunostaining for the androgen receptor and p63, a basal epithelial cell marker, we demonstrated that the menin-negative prostate cancer cells did not display p63 expression and that the androgen receptor was expressed but more heterogeneous in these lesions. Furthermore, our data showed that the expression of the cyclin-dependent kinase inhibitor CDKN1B (p27), a Men1 target gene known to be inactivated during prostate cell tumorigenesis, was notably decreased in the prostate cancers that developed in the mutant mice.ConclusionOur work suggests the possible involvement of Men1 inactivation in the tumorigenesis of the prostate gland.


Journal of Endocrinology | 2008

Tumour suppressor menin is essential for development of the pancreatic endocrine cells

Sandra Fontanière; Bertrand Duvillié; Raphael Scharfmann; Christine Carreira; Zhao-Qi Wang; Chang-Xian Zhang

Mutations of the multiple endocrine neoplasia type 1 (MEN1) gene predispose patients to MEN1 that affects mainly endocrine tissues, suggesting important physiological functions of the gene in adult endocrine cells. Homozygous disruption of Men1 in mice causes embryonic lethality, whereas the eventual involvement of the gene in embryonic development of the endocrine cells remains unknown. Here, we show that homozygous Men1 knockout mice demonstrate a reduced number of glucagon-positive cells in the E12.5 pancreatic bud associated with apoptosis, whereas the exocrine pancreas development in these mice is not affected. Our data suggest that menin is involved in the survival of the early pancreatic endocrine cells during the first developmental transition. Furthermore, chimerism assay revealed that menin has an autonomous and specific effect on the development of islet cells. In addition, using pancreatic bud culture mimicking the differentiation of alpha- and beta-cells during the second transition, we show that loss of menin leads to the failure of endocrine cell development, altered pancreatic structure and a markedly decreased number of cells expressing neurogenin 3, indicating that menin is also required at this stage of the endocrine pancreas development. Taken together, our results suggest that menin plays an indispensable role in the development of the pancreatic endocrine cells.


International Journal of Cancer | 2017

Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer

Devasena Anantharaman; Behnoush Abedi-Ardekani; Daniel C. Beachler; Tarik Gheit; Andrew F. Olshan; Kathy Wisniewski; Victor Wünsch-Filho; Tatiana Natasha Toporcov; Eloiza Helena Tajara; José Eduardo Levi; Raquel Ajub Moyses; Stefania Boccia; Gabriella Cadoni; Guido Rindi; Wolfgang Ahrens; Franco Merletti; David I. Conway; Sylvia Wright; Christine Carreira; Helene Renard; Priscilia Chopard; Sandrine McKay-Chopin; Ghislaine Scelo; Massimo Tommasino; Paul Brennan; Gypsyamber D'Souza

Human papillomavirus (HPV) causes oropharyngeal squamous cell carcinoma (OPSCC), although strongly divergent results have been reported regarding the prevalence of HPV16 in different countries, whether this represents important differences in etiology remains unclear. Applying rigorous protocols for sample processing, we centrally evaluated 1,420 head and neck tumors (533 oropharynx, 395 oral cavity and 482 larynx) from studies conducted in the US, Europe and Brazil for mucosal HPV DNA and p16INK4a expression to evaluate regional heterogeneity in the proportion of HPV16‐associated OPSCC and other head and neck cancer, and to assess covariates associated with the risk of HPV16‐positive OPSCC. While majority of OPSCC in the US (60%) were HPV16‐positive, this proportion was 31% in Europe and only 4% in Brazil (p < 0.01). Similar differences were observed for other head and neck tumors, ranging from 7% in the US and 5% in Europe, to 0% in South America. The odds of HPV16‐positive OPSCC declined with increasing pack years of smoking (OR: 0.75; 95% CI: 0.64–0.87) and drink years of alcohol use (OR: 0.64; 95% CI: 0.54–0.76). These results suggest that while the contribution of HPV16 is substantial for the oropharynx, it remains limited for oral cavity and laryngeal cancers.


Journal of Medical Virology | 2014

Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma.

Tarik Gheit; Behnoush Abedi-Ardekani; Christine Carreira; Carlos G. Missad; Massimo Tommasino; Mariela C. Torrente

Role of human papillomavirus (HPV) in laryngeal carcinoma remains controversial. The aim of this study is to evaluate the role of HPV in laryngeal squamous cell carcinoma by determining presence of markers of viral infection. HPV DNA and E6*I mRNA status was determined by type‐specific E7 PCR bead‐based multiplex genotyping and RT‐PCR assays in laryngeal squamous cell carcinoma biopsy samples. p16INK4a and COX‐2 expression was determined by immunohistochemistry. Four cases out of 32 (13%) were HPV DNA+: HPV 11 (n = 1), HPV 31 (n = 3), HPV 59 (n = 1). One double infection: HPV 11 and HPV 31. p16INK4a was overexpressed in three cases (9%) and COX‐2 in 17 cases (53%). Two of four HPV DNA+ samples had E6*I mRNA for HPV 31 and overexpressed p16INK4a and COX‐2. HPV appears to play an active role in a small subset of laryngeal squamous cell carcinoma. p16INK4a can be used as a surrogate marker of transcriptionally active HPV infection; COX‐2 expression had no correlation with HPV DNA and/or RNA positivity. J. Med. Virol. 86:642–646, 2014.


Virology | 2011

Human papillomavirus type 16 E6 inhibits p21WAF1 transcription independently of p53 by inactivating p150Sal2

Peggy Parroche; Majid Touka; Mariam Mansour; Véronique Bouvard; Amélie Thépot; Rosita Accardi; Christine Carreira; Guillaume Roblot; Bakary S. Sylla; Uzma A. Hasan; Massimo Tommasino

HPV16 E6 deregulates G1/S cell cycle progression through p53 degradation preventing transcription of the CDK inhibitor p21(WAF1). However, additional mechanisms independent of p53 inactivation appear to exist. Here, we report that HPV16 E6 targets the cellular factor p150(Sal2), which positively regulates p21(WAF1) transcription. HPV16 E6 associates with p150(Sal2), inducing its functional inhibition by preventing its binding to cis elements on the p21(WAF1) promoter. A HPV16 E6 mutant, L110Q, which was unable to bind p150(Sal2), did not affect the ability of the cellular protein to bind p21(WAF1) promoter, underlining the linkage between these events. These data describe a novel mechanism by which HPV16 E6 induces cell cycle deregulation with a p53-independent pathway. The viral oncoprotein targets p150(Sal2), a positive transcription regulator of p21(WAF1) gene, preventing G1/S arrest and allowing cellular proliferation and efficient viral DNA replication.

Collaboration


Dive into the Christine Carreira's collaboration.

Top Co-Authors

Avatar

Massimo Tommasino

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Tarik Gheit

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Behnoush Abedi-Ardekani

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Sandrine McKay-Chopin

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Ghislaine Scelo

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Paul Brennan

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Bakary S. Sylla

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Devasena Anantharaman

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Geoffroy Durand

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Guillaume Roblot

École Normale Supérieure

View shared research outputs
Researchain Logo
Decentralizing Knowledge